Comparison · NCT02006472-c73a0f93
Pridopidine 45 mg BID vs Placebo: Total Functional Capacity Responder Rate in Early HD
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Pridopidine 45 mg BID vs Placebo: Total Functional Capacity Responder Rate in Early HD. Trial comparisons, record NCT02006472-c73a0f93. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02006472-c73a0f93
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.811 | 0.658 | 0.905 | wilson | |
| Risk in group 2 | 0.488 | 0.343 | 0.635 | wilson | |
| Risk difference, group 1 minus group 2 | 0.323 | 0.111 | 0.496 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.66 | 1.17 | 2.36 | log | |
| Odds ratio, group 1 over group 2 | 4.5 | 1.61 | 12.5 | log | |
| Number needed to treat, for one more participant with the outcome on Pridopidine 45 mg BID than on Placebo | 3.1 | 2.02 | 9.03 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Pridopidine 45 mg BID | Pridopidine given as hard capsules, twice daily~Patients received a starting dose of pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52. | 30 | 37 | OG001 |
| Group 2 | Placebo | Pridopidine matching placebo (hard capsules)~Patients received a starting dose of placebo matching pridopidine 22.5 mg and were during the first 4 weeks of treatment titrated to their randomized dose level. The randomized dose level was then to be maintained for the remainder of the treatment period through Week 52. | 20 | 41 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- POST_HOC
- Title
- Total Functional Capacity Responder Rate in Early HD
- Description
The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning.~Responder was defined as a TFC change to Week 52 of TFC\>=0.
- Time frame
- 52 weeks
- Population
FAS i.e. pts receiving ≥1 dose of study drug and with ≥1 post-BL efficacy assessment; pts with early HD defined by BL TFC score ≥7 who completed 52 weeks.~The study tested 4 pridopidine doses on TMS for 26 w. Due to a new understanding on pridopidine's mechanism of action (S1R agonist), the study was extended to 52w to assess TFC in all HD. A post-hoc analysis for the 45 mg bid dose was performed for TFC in early HD, and the dose was chosen for Phase 3.
Source ClinicalTrials.gov
Trial
- Title
- A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
- NCT number
- NCT02006472
- Phases
- PHASE2
- Conditions
- Huntington's Disease
- Interventions
- Pridopidine, Placebo
- Lead sponsor
- Prilenia
- Results first posted
- 2021-07-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02006472?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02006472-c73a0f93